New hope for tough cancers: veonetinib trial launches
NCT ID NCT05363280
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests an oral drug called veonetinib (AL8326) in 80 adults with advanced small cell lung cancer, non-small cell lung cancer, or renal cell carcinoma who have already tried at least one prior treatment. The study aims to find the best dose and see if the drug can shrink tumors or slow cancer growth. Participants will take veonetinib pills daily and be monitored for side effects and response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
veonetinib (AL8326)
What this could lead to
If successful, this could provide a new treatment option for people with advanced lung or kidney cancers who have not responded to prior therapies.
What could go wrong
This is an early Phase 2 trial with only 80 participants, so results may not apply to all patients. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-••••
Contact
-
Cleveland Clinic Florida
WITHDRAWNWeston, Florida, 33331, United States
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario Ramón Y Cajal
RECRUITINGMadrid, Spain
Contact Phone: •••-•••-••••
Contact
-
Northwestern University
COMPLETEDChicago, Illinois, 60611, United States
-
Siteman Cancer Center, Washington University
RECRUITINGSt Louis, Missouri, 63130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••